<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479918</url>
  </required_header>
  <id_info>
    <org_study_id>HGBL DH and HGBL NOS</org_study_id>
    <nct_id>NCT03479918</nct_id>
  </id_info>
  <brief_title>R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)</brief_title>
  <official_title>Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-BL-M-04 and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise Specified</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elena N.Parovichnikova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-BL-04 with and
      without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed
      patients with High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not
      Otherwise Specified.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients initially are randomized into 4 arms:

      the first arm R-DA-EPOCH-21 the second arm R-BL-M-04 the third arm R-DA-EPOCH-21 + auto-SCT
      the fourth arm of R-BL-M-04 + auto-SCT Patients who achieved complete remission after 6
      cycles of R-DA-EPOCH-21 or 4 cycles of R-BL-M-04 immunochemotherapy continue to be under
      observation (1st and 2nd arms) or continue treatment with Rituximab +
      BCNU+Etoposid+Ara-C+Melphalan (R-BEAM) followed by auto-SCT (3rd and 4th arms).

      Patients who did not achieve complete remission with PET-CT data (4-5 Deauville points) are
      removed from the protocol and undergoing second-line therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Factorial Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency of progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>1 year</time_frame>
    <description>Frequency of complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>1 year</time_frame>
    <description>Frequency of partial remission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Probability of relapse or progression</measure>
    <time_frame>2 years</time_frame>
    <description>Probability of relapse or progression</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lymphoma, High-Grade</condition>
  <arm_group>
    <arm_group_label>R-DA-EPOCH-21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-BL-M-04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Course A:
Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.
Course C:
Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.
Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-DA-EPOCH-21 + auto-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-BL-M-04 + auto-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-DA-EPOCH-21</intervention_name>
    <description>R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.</description>
    <arm_group_label>R-DA-EPOCH-21</arm_group_label>
    <other_name>R-DA-EPOCH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-BL-M-04</intervention_name>
    <description>R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.</description>
    <arm_group_label>R-BL-M-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-DA-EPOCH-21 + auto-SCT</intervention_name>
    <description>R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.</description>
    <arm_group_label>R-DA-EPOCH-21 + auto-SCT</arm_group_label>
    <other_name>R-DA-EPOCH + auto-SCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-BL-M-04 + auto-SCT</intervention_name>
    <description>R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.</description>
    <arm_group_label>R-BL-M-04 + auto-SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First established the diagnosis of HGBL DH or HGBL-NOS.

          2. No previous treatment with chemotherapy and/or radiation therapy of DLBCL

          3. Informed consent of the patient.

        Exclusion Criteria:

          1. Pretreated lymphoma.

          2. HIV-associated lymphoma

          3. Congestive heart failure, unstable angina, severe cardiac arrhythmias and conduction
             disturbances, myocardial infarction.

          4. Renal insufficiency (serum creatinine greater than 0.2 mmol/L) (except cases with
             specific kidney infiltration, urinary tract compression by tumour conglomerate or
             presence of uric acid nephropathy due to massive cytolysis syndrome).

          5. Liver failure (except cases with liver tumour infiltration), acute hepatitis or active
             phase of chronic hepatitis B or C with serum bilirubin greater than 1.5 standards,
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 3
             standards, prothrombin index less than 70%.

          6. Severe pneumonia (except cases with specific lungs infiltration), accompanied by
             respiratory failure (dyspnea &gt; 30 in min., hypoxemia less than 70 mm Hg, when it is
             impossible to compensate situation in 2-3 days).

          7. Life-threatening bleeding (gastrointestinal, intracranial), with exception of bleeding
             due to tumour infiltration of organs (stomach, intestines, uterus, etc.) and
             disseminated intravascular coagulation due to underlying disease complications after
             their successful conservative treatment.

          8. Severe mental disorders (delusions, severe depressive syndrome and other
             manifestations of productive symptoms) not related to specific infiltration of a
             central nervous system.

          9. Decompensated diabetes.

        11. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Parovichnokva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Hematology, Moscow, Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Misyurina, PhD</last_name>
    <phone>9096373249</phone>
    <email>anna.lukina1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey Kravchenko, PhD</last_name>
    <phone>+74956132446</phone>
    <email>krav-hsc-ramn@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Research Center for Hematology</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Parovichnikova, MD, PhD</last_name>
      <email>director@blood.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey Kravchenko, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Misyurina, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aminat Magomedova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey Kulikov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alla Kovrigina, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Obukhova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>Head of BMT department, National Research Center for Hematology, Russia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

